Login
$GPCR
$18.56 -$0.01 (0.05%) After hours

$GPCR 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition

Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028

08 Sep 2026 8-K: Regulation FD Disclosure; Other Events

2 This presentation contains “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securi ties Litigation Reform Act of 1995. All statements other than statements of historical fact are statemen...

06 Aug 2026 8-K: Results of Operations and Financial Condition

First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management

18 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 17, 2026, Structure Therapeutics Inc. (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “Annual General Meeting”). As of April 20, 2026, the record date for the Annual General Meeting, 213,213,565 ordinary...

07 May 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

Reference is made to that certain Sales Agreement, entered into as of August 6, 2025 (the “Original Sales Agreement”), by and among Structure Therapeutics Inc., an exempted company with limited liability incorporated under the laws of th...

15 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

SAN FRANCISCO, April 14, 2026 – Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announ...

16 Mar 2026 8-K: Regulation FD Disclosure; Other Events

1 March 16, 2026 Aleniglipron Topline ACCESS II and Supplementary Studies

26 Feb 2026 8-K: Results of Operations and Financial Condition

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks

05 Jan 2026 8-K: Entry into a Material Definitive Agreement

On December 30, 2025, Gasherbrum Bio, Inc. (“Gasherbrum”), a wholly-owned subsidiary of Structure Therapeutics Inc. (the “Company”), entered into an agreement (the “GNE Agreement”) with Genentech, Inc. (“Genentech”) and F. Hoffmann-La Ro...

10 Dec 2025 8-K: Other Events

Introductory. Structure Therapeutics Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Und...

08 Dec 2025 8-K: Regulation FD Disclosure; Other Events

1 December 8, 2025 Aleniglipron Topline ACCESS Phase 2b Results

06 Nov 2025 8-K: Results of Operations and Financial Condition

Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025

06 Aug 2025 8-K: Results of Operations and Financial Condition

Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts

25 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 23, 2025, Structure Therapeutics Inc. (the “Company”) held its 2025 Annual General Meeting of Shareholders (the “Annual General Meeting”). As of April 17, 2025, the record date for the Annual General Meeting, 172,610,249 ordinary...

08 May 2025 8-K: Results of Operations and Financial Condition

Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025

27 Feb 2025 8-K: Results of Operations and Financial Condition

Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025

17 Dec 2024 8-K: Regulation FD Disclosure

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

13 Nov 2024 8-K: Results of Operations and Financial Condition

Oral small molecule amylin receptor agonist development candidate

17 Sep 2024 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more

Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

27 Aug 2024 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support